Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5269877
Max Phase: Preclinical
Molecular Formula: C34H27N6NaO12S4
Molecular Weight: 838.88
Associated Items:
ID: ALA5269877
Max Phase: Preclinical
Molecular Formula: C34H27N6NaO12S4
Molecular Weight: 838.88
Associated Items:
Canonical SMILES: Nc1ccc(/N=N/c2ccc(/C=C/c3ccc(/N=N/c4ccc(N)c5ccc(S(=O)(=O)O)cc45)cc3S(=O)(=O)O)c(S(=O)(=O)O)c2)c2cc(S(=O)(=O)O)ccc12.[NaH]
Standard InChI: InChI=1S/C34H26N6O12S4.Na.H/c35-29-11-13-31(27-17-23(53(41,42)43)7-9-25(27)29)39-37-21-5-3-19(33(15-21)55(47,48)49)1-2-20-4-6-22(16-34(20)56(50,51)52)38-40-32-14-12-30(36)26-10-8-24(18-28(26)32)54(44,45)46;;/h1-18H,35-36H2,(H,41,42,43)(H,44,45,46)(H,47,48,49)(H,50,51,52);;/b2-1+,39-37+,40-38+;;
Standard InChI Key: DXMXZCHPIBYHHS-BKNXFVSTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 838.88 | Molecular Weight (Monoisotopic): 838.0492 | AlogP: 7.15 | #Rotatable Bonds: 10 |
Polar Surface Area: 318.96 | Molecular Species: ACID | HBA: 14 | HBD: 6 |
#RO5 Violations: 4 | HBA (Lipinski): 18 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: -3.43 | CX Basic pKa: 2.67 | CX LogP: 1.99 | CX LogD: -3.33 |
Aromatic Rings: 6 | Heavy Atoms: 56 | QED Weighted: 0.03 | Np Likeness Score: -0.32 |
1. Wei J, Wang H, Zheng Q, Zhang J, Chen Z, Wang J, Ouyang L, Wang Y.. (2022) Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers., 241 [PMID:35939992] [10.1016/j.ejmech.2022.114650] |
Source(1):